通过降低PD-L1的调节,APLNR抑制了鼻癌的生长和免疫逃脱
Ying Liu1, Nan Li1, Yilin Guo1
1Department of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Medical Laboratory Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
阿佩林受体 (APLNR) 抑制了PD-L1表达和在鼻癌 (NPC) 中的免疫逃逸. 用PD-L1抗体向APLNR可能会改善NPC免疫疗法的结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 在G蛋白合受体信号传递中.
背景情况:
- 以前的研究表明,阿佩林受体 (APLNR) 抑制鼻癌 (NPC) 的生长和转移.
- APLNR在NPC中调节PD-L1表达和免疫逃逸中的作用仍然没有被阐明.
研究的目的:
- 研究APLNR在NPC中调节PD-L1表达和免疫逃逸中的作用.
- 为了阐明底层的分子机制.
- 评估针对APLNR与PD-L1阻断结合的治疗潜力.
主要方法:
- 在NPC组织和细胞中分析APLNR和PD-L1表达和相关性.
- 在体外和体内研究APLNR对PD-L1表达和机制的影响.
- 在裸体老鼠异种移植模型中对APLNR向和PD-L1抗体治疗的综合评估.
主要成果:
- 在NPC中,APLNR表达与PD-L1负相关.
- 通过与JAK1.1相互作用,APLNR通过阻断JAK1/STAT1通路来抑制PD-L1.
- APLNR通过增加IFN-γ分泌,CD8+T细胞透和减少T细胞亡来增强抗瘤免疫力.
- 针对APLNR和PD-L1抗体的联合疗法在体内抑制NPC生长方面表现出更高的疗效.
结论:
- 在NPC中,APLNR在调节PD-L1表达和免疫逃逸方面发挥着新的作用.
- APLNR代表了增强NPC免疫疗法的潜在治疗标.
更多相关视频
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
相关概念视频
The Intrinsic Apoptotic Pathway
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Abnormal Proliferation
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Experimental RNAi
